Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-058254
Filing Date
2025-04-24
Accepted
2025-04-24 20:02:27
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10631
  Complete submission text file 0000950170-25-058254.txt   12409
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Subject) CIK: 0001029125 (see all company filings)

EIN.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88985 | Film No.: 25869437
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 9922 JEFFERSON BOULEVARD CULVER CITY CA 90232
Business Address 310-836-6400
Nant Capital, LLC (Filed by) CIK: 0001675758 (see all company filings)

EIN.: 300750613
Type: SCHEDULE 13D/A